MDM1

Across TCGA pan-cancer cohorts, MDM1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MDM1 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MDM1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MDM1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where MDM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.726	0.282	.014	11	view →
CCRCC	DFS	Median	All	0.825	0.646	.022	8	view →
LSCC	DFS	Quartile	II,III,IV	0.827	0.970	.022	4	view →
UCEC	OS	Median	All	0.857	0.965	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MDM1–PDAC (DFS)

Open the PDAC breakdown →